PGS Publication: PGP000184

Publication Information (EuropePMC)
Title Differential associations of allergic disease genetic variants with developmental profiles of eczema, wheeze and rhinitis.
PubMed ID 31441980(Europe PMC)
doi 10.1111/cea.13485
Publication Date Oct. 15, 2019
Journal Clin Exp Allergy
Author(s) Clark H, Granell R, Curtin JA, Belgrave D, Simpson A, Murray C, Henderson AJ, Custovic A, Paternoster L.
Released in PGS Catalog: May 28, 2021

Associated Polygenic Score(s)

Filter PGS by Participant Ancestry
Individuals included in:
G - Source of Variant Associations (GWAS)
D - Score Development/Training
E - PGS Evaluation
List of ancestries includes:
Display options:
Ancestry legend
Multi-ancestry (including European)
Multi-ancestry (excluding European)
African
East Asian
South Asian
Additional Asian Ancestries
European
Greater Middle Eastern
Hispanic or Latin American
Additional Diverse Ancestries
Not Reported

PGS Developed By This Publication

Polygenic Score ID & Name PGS Publication ID (PGP) Reported Trait Mapped Trait(s) (Ontology) Number of Variants Ancestry distribution
GWAS
Dev
Eval
Scoring File (FTP Link)
PGS000780
(PRS135_allergy)
PGP000184 |
Clark H et al. Clin Exp Allergy (2019)
Allergic disease allergic disease 135
-
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000780/ScoringFiles/PGS000780.txt.gz

Performance Metrics

Disclaimer: The performance metrics are displayed as reported by the source studies. It is important to note that metrics are not necessarily comparable with each other. For example, metrics depend on the sample characteristics (described by the PGS Catalog Sample Set [PSS] ID), phenotyping, and statistical modelling. Please refer to the source publication for additional guidance on performance.

PGS Performance
Metric ID (PPM)
Evaluated Score PGS Sample Set ID
(PSS)
Performance Source Trait PGS Effect Sizes
(per SD change)
Classification Metrics Other Metrics Covariates Included in the Model PGS Performance:
Other Relevant Information
PPM002024 PGS000780
(PRS135_allergy)
PSS001008|
Ancestry Not Reported|
897 individuals
PGP000184 |
Clark H et al. Clin Exp Allergy (2019)
Reported Trait: Atopic March Relative Risk Ratio (RRR): 1.89 [1.4, 2.55] Only 134 SNPs from the 135 SNP PRS were utilised. Rs10305290 was not included as the SNP was monomorphic.
PPM002025 PGS000780
(PRS135_allergy)
PSS001007|
Multi-ancestry (including European)|
7,242 individuals
PGP000184 |
Clark H et al. Clin Exp Allergy (2019)
Reported Trait: Atopic March Relative Risk Ratio (RRR): 1.99 [1.74, 2.29] For the MAAS cohort, only 134 SNPs from the 135 SNP PRS were utilised. Rs10305290 was not included as the SNP was monomorphic.
PPM002026 PGS000780
(PRS135_allergy)
PSS001008|
Ancestry Not Reported|
897 individuals
PGP000184 |
Clark H et al. Clin Exp Allergy (2019)
Reported Trait: Persistent eczema and wheeze Relative Risk Ratio (RRR): 1.38 [1.01, 1.9] Only 134 SNPs from the 135 SNP PRS were utilised. Rs10305290 was not included as the SNP was monomorphic.
PPM002027 PGS000780
(PRS135_allergy)
PSS001007|
Multi-ancestry (including European)|
7,242 individuals
PGP000184 |
Clark H et al. Clin Exp Allergy (2019)
Reported Trait: Persistent eczema and wheeze Relative Risk Ratio (RRR): 1.39 [1.22, 1.6] For the MAAS cohort, only 134 SNPs from the 135 SNP PRS were utilised. Rs10305290 was not included as the SNP was monomorphic.
PPM002028 PGS000780
(PRS135_allergy)
PSS001008|
Ancestry Not Reported|
897 individuals
PGP000184 |
Clark H et al. Clin Exp Allergy (2019)
Reported Trait: Persistent eczema with late-onset rhinitis Relative Risk Ratio (RRR): 1.35 [1.04, 1.76] Only 134 SNPs from the 135 SNP PRS were utilised. Rs10305290 was not included as the SNP was monomorphic.
PPM002029 PGS000780
(PRS135_allergy)
PSS001007|
Multi-ancestry (including European)|
7,242 individuals
PGP000184 |
Clark H et al. Clin Exp Allergy (2019)
Reported Trait: Persistent eczema with late-onset rhinitis Relative Risk Ratio (RRR): 1.51 [1.35, 1.68] For the MAAS cohort, only 134 SNPs from the 135 SNP PRS were utilised. Rs10305290 was not included as the SNP was monomorphic.
PPM002030 PGS000780
(PRS135_allergy)
PSS001008|
Ancestry Not Reported|
897 individuals
PGP000184 |
Clark H et al. Clin Exp Allergy (2019)
Reported Trait: Persistent wheeze with late-onset rhinitis Relative Risk Ratio (RRR): 1.58 [1.22, 2.03] Only 134 SNPs from the 135 SNP PRS were utilised. Rs10305290 was not included as the SNP was monomorphic.
PPM002031 PGS000780
(PRS135_allergy)
PSS001007|
Multi-ancestry (including European)|
7,242 individuals
PGP000184 |
Clark H et al. Clin Exp Allergy (2019)
Reported Trait: Persistent wheeze with late-onset rhinitis Relative Risk Ratio (RRR): 1.44 [1.3, 1.6] For the MAAS cohort, only 134 SNPs from the 135 SNP PRS were utilised. Rs10305290 was not included as the SNP was monomorphic.
PPM002032 PGS000780
(PRS135_allergy)
PSS001007|
Multi-ancestry (including European)|
7,242 individuals
PGP000184 |
Clark H et al. Clin Exp Allergy (2019)
Reported Trait: Transient wheeze Relative Risk Ratio (RRR): 1.11 [1.02, 1.21] For the MAAS cohort, only 134 SNPs from the 135 SNP PRS were utilised. Rs10305290 was not included as the SNP was monomorphic.
PPM002033 PGS000780
(PRS135_allergy)
PSS001007|
Multi-ancestry (including European)|
7,242 individuals
PGP000184 |
Clark H et al. Clin Exp Allergy (2019)
Reported Trait: Eczema only Relative Risk Ratio (RRR): 1.16 [1.08, 1.24] For the MAAS cohort, only 134 SNPs from the 135 SNP PRS were utilised. Rs10305290 was not included as the SNP was monomorphic.
PPM002034 PGS000780
(PRS135_allergy)
PSS001008|
Ancestry Not Reported|
897 individuals
PGP000184 |
Clark H et al. Clin Exp Allergy (2019)
Reported Trait: Rhinitis only Relative Risk Ratio (RRR): 1.32 [1.06, 1.64] Only 134 SNPs from the 135 SNP PRS were utilised. Rs10305290 was not included as the SNP was monomorphic.
PPM002035 PGS000780
(PRS135_allergy)
PSS001007|
Multi-ancestry (including European)|
7,242 individuals
PGP000184 |
Clark H et al. Clin Exp Allergy (2019)
Reported Trait: Rhinitis only Relative Risk Ratio (RRR): 1.21 [1.12, 1.31] For the MAAS cohort, only 134 SNPs from the 135 SNP PRS were utilised. Rs10305290 was not included as the SNP was monomorphic.

Evaluated Samples

PGS Sample Set ID
(PSS)
Phenotype Definitions and Methods Participant Follow-up Time Sample Numbers Age of Study Participants Sample Ancestry Additional Ancestry Description Cohort(s) Additional Sample/Cohort Information
PSS001007 Cases were individuals with latent classes of allergic diseases (LCADs). LCADs includes atopic march (defined as having a high probability of eczema from infancy to age 11 years with increased probability of wheeze overtime. For rhinitis, the probability increases from zero at age 1 year to almost 100% by 8 years. Eczema developed first, followed by wheeze, and then rhinitis) , persistent eczema and wheeze (defined as having a similar probability of wheeze and eczema throughout childhood, likely as co-morbidities, with a low probability of rhinitis throughout childhood), persistent eczema with late‐onset rhinitis (defined as having increased eczema prevalence from ~70% in early life to 95% at age 5 years, with little resolution at 11 years. The probability of rhinitis increases to almost 100% by age 8 years with low probability of wheeze throughout childhood), persistent wheeze with late‐onset rhinitis (definned as having a high probability of wheeze throughout childhood, with increasing probability of rhinitis to almost 100% by age 11 years. Probability of eczema being low, declining steadily at age 11 years), transient wheeze (defined as having a high probability of wheeze within the first 5 years, with remission by age 8 years, and a very low probability of eczema and rhinitis throughout childhood), eczema only (defined as having a high probability of eczema throughout life, peaking at ~80% at age 5 years, then declining steadily to a 50% probability at age 11 years) and rhinitis only (defined as having an increasing probability of rhinitis from age 5 to 11 years, but no wheeze or eczema). Of the 575 cases, 230 had atopic march, 227 had persistent eczema and wheeze, 380 had persistent eczema with late-onset rhinitis, 429 had persistent wheeze with late-onset rhinitis, 599 had transient wheeze, 1089 had eczema only and 791 had rhinitis only.
[
  • 3,745 cases
  • , 3,497 controls
]
,
51.45 % Male samples
European, NR European = 6345, NR = 897 ALSPAC, MAAS Possible sample overlap (up to 88%) between this dataset and the dataset used to source variants for the PRS.
PSS001008 Cases were individuals with latent classes of allergic diseases (LCADs). LCADs includes atopic march (defined as having a high probability of eczema from infancy to age 11 years with increased probability of wheeze overtime. For rhinitis, the probability increases from zero at age 1 year to almost 100% by 8 years. Eczema developed first, followed by wheeze, and then rhinitis) , persistent eczema and wheeze (defined as having a similar probability of wheeze and eczema throughout childhood, likely as co-morbidities, with a low probability of rhinitis throughout childhood), persistent eczema with late‐onset rhinitis (defined as having increased eczema prevalence from ~70% in early life to 95% at age 5 years, with little resolution at 11 years. The probability of rhinitis increases to almost 100% by age 8 years with low probability of wheeze throughout childhood), persistent wheeze with late‐onset rhinitis (definned as having a high probability of wheeze throughout childhood, with increasing probability of rhinitis to almost 100% by age 11 years. Probability of eczema being low, declining steadily at age 11 years), transient wheeze (defined as having a high probability of wheeze within the first 5 years, with remission by age 8 years, and a very low probability of eczema and rhinitis throughout childhood), eczema only (defined as having a high probability of eczema throughout life, peaking at ~80% at age 5 years, then declining steadily to a 50% probability at age 11 years) and rhinitis only (defined as having an increasing probability of rhinitis from age 5 to 11 years, but no wheeze or eczema). Of the 575 cases, 55 had atopic march, 46 had persistent eczema and wheeze, 73 had persistent eczema with late-onset rhinitis, 81 had persistent wheeze with late-onset rhinitis, 65 had transient wheeze, 141 had eczema only and 114 had rhinitis only.
[
  • 575 cases
  • , 322 controls
]
,
53.8 % Male samples
Not reported MAAS